Hua Medicine (Shanghai) Ltd. (HUMDF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 1.75 means the share price is 1.75 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $303M is the value of all shares combined. Beta 1.11: the stock has moved about 11% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHua Medicine (Shanghai) Ltd. (HUMDF) trades at $0.3039. Hua Medicine (Shanghai) Ltd. is a clinical-stage drug development company focused on therapies for diabetes in China. Market cap: $303M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 15, 2026Analyst Coverage for HUMDF: HUMDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HUMDF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
HUMDF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Hua Medicine (Shanghai) Ltd. (HUMDF) Healthcare & Pipeline Overview
Hua Medicine (Shanghai) Ltd., a clinical-stage pharmaceutical company based in China, specializes in developing innovative therapies for Type 2 Diabetes. Their primary focus is Dorzagliatin (HMS5552), an oral drug currently undergoing clinical trials, positioning them within the competitive landscape of diabetes treatment solutions.
What Is the Investment Thesis for HUMDF?
Hua Medicine's investment thesis centers on the potential of Dorzagliatin to address the significant and growing market for diabetes treatments in China. With a P/E ratio of 1.75 and a gross margin of 52.5%, the company shows promise in profitability. Key catalysts include the successful completion of ongoing clinical trials and regulatory approval for Dorzagliatin in China. The company's focus on combination therapies could expand its market reach and provide a competitive advantage. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established diabetes treatments. The company's beta of 1.11 indicates slightly higher volatility compared to the market.
Based on FMP financials and quantitative analysis
HUMDF Key Highlights
Market capitalization of $303M indicates the company's current valuation in the market.
- P/E ratio of 1.75 suggests the company might be undervalued compared to its earnings.
- Profit margin of 290.3% demonstrates strong profitability, potentially driven by successful clinical trials.
- Gross margin of 52.5% indicates efficient cost management in drug development and manufacturing.
- Beta of 1.11 suggests the stock is slightly more volatile than the market.
Who Are HUMDF's Competitors?
HUMDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AGYTF Allergy Therapeutics plc | $0.15 | 0.00% | $756M | — |
| BOIRF Boiron S.A. | $31.50 | 0.00% | $547M | — |
| CLVLY Clinuvel Pharmaceuticals Limited | $6.74 | +0.97% | $340M | — |
| CRLBF Cresco Labs Inc. | $0.73 | -4.21% | $258M | 459-signal |
| HNSBF Hansa Biopharma AB (publ) | $3.70 | 0.00% | $369M | — |
| EMBC Embecta Corp. | $4.89 | -4.49% | $290M | 755-pillar |
| ELTP Elite Pharmaceuticals, Inc. | $0.25 | -2.33% | $270M | 539-signal |
| SNDL SNDL Inc. | $1.35 | +1.12% | $353M | 355-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are HUMDF's Key Strengths?
Novel drug candidate (Dorzagliatin) with a unique mechanism of action.
- Focus on the large and growing Chinese diabetes market.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its drug candidates.
What Are HUMDF's Weaknesses?
Clinical-stage company with no currently approved products.
- Reliance on the success of Dorzagliatin.
- Limited financial resources compared to larger pharmaceutical companies.
- Exposure to regulatory risks in China.
What Could Drive HUMDF Stock Higher?
HUMDF catalyst: Completion of Phase I clinical trials for Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin.
- Development of mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia.
- Exploration of Dorzagliatin in combination with Pioglitazone for NASH.
- Potential partnerships and licensing agreements with larger pharmaceutical companies.
- Expansion into international markets with high diabetes prevalence.
What Are the Key Risks for HUMDF?
Clinical trial failures or delays for Dorzagliatin.
- Regulatory hurdles and changes in government policies in China.
- Competition from established diabetes treatments.
- Limited financial resources compared to larger pharmaceutical companies.
- Reliance on the success of Dorzagliatin.
What Are the Growth Opportunities for HUMDF?
- Expansion of Dorzagliatin into Combination Therapies: Hua Medicine is actively pursuing combination therapies involving Dorzagliatin with existing diabetes drugs like Metformin and Sitagliptin. This strategy allows for a broader patient reach and can address different stages and complexities of Type 2 Diabetes. The market for combination diabetes therapies is projected to grow as physicians increasingly adopt personalized treatment approaches. Timeline: Ongoing clinical trials with potential for market launch within 3-5 years pending regulatory approvals.
- Geographic Expansion within China: While headquartered in Beijing, Hua Medicine has the opportunity to expand its commercial presence across different regions of China. Given the varying demographics and healthcare access across the country, a targeted regional expansion strategy can significantly boost sales and market penetration. The Chinese diabetes market is vast and diverse, offering ample opportunities for growth. Timeline: Gradual expansion over the next 3-5 years, contingent on regulatory approvals and market access.
- Development of mGLUR5 for Parkinson's Disease: Hua Medicine is diversifying its pipeline by developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia. This expands the company's focus beyond diabetes and into another significant therapeutic area with unmet medical needs. The market for Parkinson's disease treatments is substantial and growing, driven by an aging population. Timeline: Early-stage development with potential for clinical trials in the next 2-3 years.
- Partnerships and Licensing Agreements: Hua Medicine can pursue strategic partnerships and licensing agreements with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This can provide access to additional funding, expertise, and distribution channels. The pharmaceutical industry is characterized by collaborations and partnerships, offering numerous opportunities for Hua Medicine. Timeline: Ongoing efforts to secure partnerships and licensing agreements.
- Expansion into International Markets: While currently focused on the Chinese market, Hua Medicine can explore opportunities to expand into other international markets with high diabetes prevalence, such as India and Southeast Asia. This would require navigating different regulatory landscapes and establishing local partnerships, but it could significantly increase the company's long-term growth potential. Timeline: Long-term strategic goal with potential for market entry in 5-7 years.
What Are HUMDF's Competitive Advantages?
- Proprietary drug candidates with patent protection.
- Clinical trial data demonstrating efficacy and safety.
- Focus on the Chinese market, with potential for regulatory advantages.
- Expertise in developing innovative diabetes therapies.
What Does HUMDF Do?
Hua Medicine (Shanghai) Ltd., founded in 2011 and headquartered in Beijing, China, is a clinical-stage drug development company dedicated to creating innovative therapies for diabetes, with a specific focus on the Chinese market. The company's lead product candidate is Dorzagliatin (HMS5552), an oral drug designed to treat Type 2 Diabetes (T2D). Dorzagliatin is currently being evaluated in Phase I clinical trials, both as a standalone treatment and in combination with existing diabetes medications like Metformin, Sitagliptin, and Empagliflozin. Hua Medicine is also exploring the potential of Dorzagliatin in combination with Pioglitazone for Non-Alcoholic Steatohepatitis (NASH), with GLP-1 for Alzheimer's disease, and for addressing late-stage T2D and Type 1 Diabetes. Beyond diabetes, Hua Medicine is developing mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia, diversifying its pipeline into other significant therapeutic areas. The company employs 168 individuals and is committed to addressing the growing unmet medical needs in diabetes care within China and beyond.
What Products and Services Does HUMDF Offer?
- Develops Dorzagliatin (HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D).
- Conducts clinical trials for Dorzagliatin as a standalone treatment and in combination with other diabetes medications.
- Explores the potential of Dorzagliatin in combination with Pioglitazone for Non-Alcoholic Steatohepatitis (NASH).
- Investigates the use of Dorzagliatin in combination with GLP-1 for Alzheimer's disease.
- Develops mGLUR5 for the treatment of Parkinson's disease levodopa-induced dyskinesia.
- Focuses on addressing the unmet medical needs in diabetes care within China.
How Does HUMDF Make Money?
- Develops and patents novel drug candidates for diabetes and other diseases.
- Conducts clinical trials to demonstrate the safety and efficacy of its drug candidates.
- Seeks regulatory approval for its drug candidates from relevant authorities.
- Commercializes its approved drugs through sales and marketing efforts, potentially through partnerships.
What Industry Does HUMDF Operate In?
Hua Medicine operates in the specialty and generic drug manufacturing industry, within the broader healthcare sector. The diabetes treatment market is substantial and growing, particularly in China, driven by increasing prevalence of the disease. The competitive landscape includes both multinational pharmaceutical companies and domestic Chinese firms. Hua Medicine's focus on Dorzagliatin, a novel oral drug for Type 2 Diabetes, positions it to potentially capture a significant share of this market, provided it can successfully navigate the regulatory approval process and demonstrate clinical efficacy.
Who Are HUMDF's Key Customers?
- Patients with Type 2 Diabetes in China.
- Healthcare providers who prescribe diabetes medications.
- Pharmaceutical companies interested in licensing or partnering on drug development.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in CNY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 49 |
| 2026-08-26 | 49 |
| 2026-08-29 | 49 |
| 2026-09-01 | 49 |
| 2026-09-04 | 49 |
| 2026-09-07 | 49 |
| 2026-09-10 | 49 |
What changed?
The score has stayed at 49.
Over the same 18 days the stock moved -2.0%.
Company Profile
Hua Medicine (Shanghai) Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shanghai, CN. The company is led by CEO Li Chen. HUMDF has traded publicly since 2021.
Hua Medicine (Shanghai) Ltd. Financial Trajectory
Hua Medicine (Shanghai) Ltd. (HUMDF) reported $55.8M in revenue for Q2 FY2026, reflecting 37.9% growth compared to the prior quarter. The company recorded a net loss of $4.4M, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, HUMDF averaged $0.04 in diluted EPS.
How Hua Medicine (Shanghai) Ltd. Is Valued
Hua Medicine (Shanghai) Ltd. carries a market capitalization of $303M, placing it in the small-cap category.
Key Financial Metrics
Return on equity for Hua Medicine (Shanghai) Ltd. stands at 107.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 75.3%, showing how much profit it generates from its asset base. HUMDF trades at a trailing price-to-earnings ratio of 1.75, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -3.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 57.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Hua Medicine (Shanghai) Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.02 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Hua Medicine (Shanghai) Ltd. has beaten Wall Street's EPS estimate in 4 of its last 7 reported quarters — more hits than misses. Reported results have landed about 47.2% above estimates on average.
HUMDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel drug candidate (Dorzagliatin) with a unique mechanism of action.
- Focus on the large and growing Chinese diabetes market.
- Experienced management team with expertise in drug development.
- Strong intellectual property protection for its drug candidates.
Bear Case
- Clinical-stage company with no currently approved products.
- Reliance on the success of Dorzagliatin.
- Limited financial resources compared to larger pharmaceutical companies.
- Exposure to regulatory risks in China.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $56M | -$4M | -$0.0045 |
| Q4 FY2025 | $40M | -$11M | -$0.01 |
| Q2 FY2025 | $32M | $177M | $0.18 |
| Q4 FY2024 | $23M | -$16M | -$0.02 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CNY at today's rate
HUMDF Latest News
-
Hua Medicine (Shanghai) Ltd. (HUMDF) Q2 2026 Earnings Call Transcript
seekingalpha.com · Aug 21, 2026
HUMDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HUMDF.
Price Targets
Wall Street price target analysis for HUMDF.
HUMDF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HUMDF; grades run from A+ (80-100) to F (below 30).
Leadership: Li Chen
CEO
Li Chen serves as the CEO of Hua Medicine (Shanghai) Ltd., leading a team of 168 employees. His background includes extensive experience in the pharmaceutical industry, with a focus on drug development and commercialization in China. He has a strong understanding of the Chinese regulatory landscape and healthcare market. Prior to joining Hua Medicine, he held leadership positions at several multinational pharmaceutical companies.
Track Record: Under Li Chen's leadership, Hua Medicine has advanced Dorzagliatin through multiple clinical trials and established partnerships with key stakeholders in the Chinese healthcare system. He has overseen the company's growth and expansion, positioning it as a leading innovator in diabetes treatment. Key milestones include successful Phase I clinical trials and strategic collaborations to expand the potential of Dorzagliatin.
HUMDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hua Medicine (Shanghai) Ltd. may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure requirements compared to major exchanges.
- Lower trading volume and liquidity, leading to potential price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or suspension of trading.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Development of Dorzagliatin, a novel drug candidate for diabetes.
- Focus on addressing the unmet medical needs in diabetes care within China.
- Experienced management team with expertise in drug development.
- Ongoing clinical trials to demonstrate the safety and efficacy of its drug candidates.
Common Questions About HUMDF (Healthcare)
Is HUMDF a good stock?
Stock Expert AI does not rate HUMDF buy, sell or hold. Hua Medicine (Shanghai) Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about HUMDF stock?
Analyst coverage of HUMDF is limited due to its OTC listing and clinical-stage nature. Key valuation metrics to consider include the potential market size for Dorzagliatin in China, the probability of successful clinical trial outcomes, and the regulatory pathway for drug approval.
What are the key factors to evaluate for HUMDF?
Evaluate HUMDF on fundamentals, analyst consensus, and risk factors. P/E: 1.75x vs the S&P 500's ~20-25x. With a P/E ratio of 1.75 and a gross margin of 52.5%, the company shows promise in profitability. Not financial advice.
How frequently does HUMDF data refresh on this page?
HUMDF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HUMDF's recent stock price performance?
Hua Medicine (Shanghai) Ltd. (HUMDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel drug candidate (Dorzagliatin) with a unique mechanism of action. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HUMDF overvalued or undervalued right now?
Hua Medicine (Shanghai) Ltd. (HUMDF) trades at 1.75x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HUMDF?
Yes, most major brokerages offer fractional shares of Hua Medicine (Shanghai) Ltd. (HUMDF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HUMDF's earnings and financial reports?
Hua Medicine (Shanghai) Ltd. (HUMDF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for HUMDF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.